November #53 : Drug Ads Add Up - by Shana Naomi Krochmal

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

How to End the Epidemic

Blame It on Your Hormones

Both Sides Now

Editor's Letter

Mailbox-November 1999

Rock of Aegis

Don't Ask, Don't Tell

Class Act

Drug Ads Add Up

Life is better with HIV, say 49% of positive folks.

"Should Marijuana Be Legal for Medical Purposes?"

Less than 3,000 Served

All the Lonely People

A Squeeze-In at the Summit

Remembrance of Things Present

Future Shock

Cho & Tell

Babe in Boyland

Bad Faith

Get Well Soon

Dr. Leather Meets Mr. Right

Ties That Bind

Supreme Sacrifice

Pregnant Poz

How to Have a Healthy Baby

Spare the Breast

Stop PCP Pills?

The Big Queasy

On the Rebound

From the Gut

Hoop Dreams

Arts

Milestones



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

November 1999

Drug Ads Add Up

by Shana Naomi Krochmal

Are pharmaceutical pitches breaking your bank? Activists have long claimed that high Rx prices result not from heavy research-and-development expenses, as the drug companies say, but from the profit motive. Yet a recent study of annual reports by DC-based AIDS Action found that the 15 largest U.S. drug companies collectively shelled out nearly three times the amount spent on r&d ($24 billion) for something else entirely: marketing ($68 billion). “The Titanic didn’t need ads to get people to the life-boats,” AIDS Action’s head, Daniel Zingale, sniffed. “They needed to get more life-boats to the people.”

But industry reps charge that the study was skewed by including administrative costs in the advertising and marketing figures. “It’s a strange mix,” said Jeff Trewitt, spokesperson for Pharmaceutical Research and Marketers of America. “Those administrative costs are legitimate.” Even so, said AIDS Action, a company should keep down overhead spending to justify “lowest possible price” claims.

One consumer with the pocketbook power to make change? The federal government, which—through its Medicaid and AIDS Drug Assistance Programs (ADAP)—is the country’s biggest payer for anti-HIV drugs ($1.5 billion annually). According to Peter Arno, professor of health economics at Albert Ein-stein Medical College, the study actually undercounted the feds’ AIDS-med bill. “The government has huge leverage to bring prices down,” he said.



[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    Sloan1
    Dallas
    Texas


    youngbloodlatino
    Columbia
    Maryland


    josebos
    Boston strong
    Massachusetts
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.